Study O O O O
Details O O O O
Long-Term O O O O
Side O O O O
Effects O O O O
of O O O O
Immune O O O O
Checkpoint O O O O
Inhibitors O O O O
, O O O O
by O O O O
Nadia O O O O
Jaber O O O O
[Immune O O O O
checkpoint O O O O
inhibitors](/Common/PopUps/popDefinition.aspx?id=CDR0000772606&version=Patient&language=en) O O O O
are O O O O
a O O O O
type O O O O
of O O O O
immunotherapy O O O O
used O O O O
to O O O O
treat O O O O
many O O O O
kinds O O O O
of O O O O
cancer. O O O O
In Reason 2 O O
some Reason 2 O O
patients, Reason 2 O O
these Reason 2 O O
drugs Reason 2 O O
can Reason 2 O O
lead Reason 2 O O
to Reason 2 O O
long-lasting Reason 2 O O
[remissions](/Common/PopUps/popDefinition.aspx?id=CDR0000045867&version=Patient&language=en). Reason 2 O O
While Reason 2 O O
doctors Reason 2 O O
are Reason 2 O O
familiar Reason 2 O O
with Reason 2 O O
the Reason 2 O O
short-term Reason 2 O O
side Reason 2 O O
effects Reason 2 O O
of Reason 2 O O
these Reason 2 O O
drugs, Reason 2 O O
less Reason 2 O O
is Reason 2 O O
known Reason 2 O O
about Reason 2 O O
the Reason 2 O O
possibility Reason 2 O O
of Reason 2 O O
long-term, Reason 2 O O
or Reason 2 O O
chronic, Reason 2 O O
side Reason 2 O O
effects. Reason 2 O O
According Reason 2 O O
to Reason 2 O O
a Reason 2 O O
new Reason 2 O O
study, Reason 2 O O
immune Reason 2 O O
checkpoint Reason 2 O O
inhibitors Reason 2 O O
can Reason 2 O O
cause Reason 2 O O
a Reason 2 O O
range Reason 2 O O
of Reason 2 O O
[long-term Reason 2 O O
side Reason 2 O O
effects](/Common/PopUps/popDefinition.aspx?id=CDR0000693593&version=Patient&language=en), Reason 2 O O
most Reason 2 O O
of Reason 2 O O
them Reason 2 O O
mild. Reason 2 O O
Immune O O O O
checkpoint O O O O
inhibitors O O O O
like O O O O
[nivolumab O O O O
(Opdivo)](https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab) O O O O
and O O O O
[pembrolizumab O O O O
(Keytruda)](https://www.cancer.gov/about-cancer/treatment/drugs/pembrolizumab) O O O O
take O O O O
the O O O O
brakes O O O O
off O O O O
of O O O O
cancer-killing O O O O
immune O O O O
cells. O O O O
But O O O O
these O O O O
activated O O O O
immune O O O O
cells O O O O
can O O O O
also O O O O
harm O O O O
healthy O O O O
tissues, O O O O
leading O O O O
to O O O O
side O O O O
effects. O O O O
Most O O O O
side O O O O
effects O O O O
of O O O O
immune O O O O
checkpoint O O O O
inhibitors O O O O
are O O O O
short-lived O O O O
(acute) O O O O
and O O O O
can O O O O
be O O O O
treated O O O O
with O O O O
[steroid O O O O
drugs](/Common/PopUps/popDefinition.aspx?id=CDR0000046601&version=Patient&language=en). O O O O
Until O O O O
now, O O O O
less O O O O
was O O O O
known O O O O
about O O O O
the O O O O
frequency, O O O O
timing, O O O O
and O O O O
spectrum O O O O
of O O O O
long-term O O O O
side O O O O
effects O O O O
of O O O O
these O O O O
treatments. O O O O
The Reason 2 O O
new Reason 2 O O
study Reason 2 O O
looked Reason 2 O O
at Reason 2 O O
real-world Reason 2 O O
data Reason 2 O O
on Reason 2 O O
people Reason 2 O O
with Reason 2 O O
[melanoma](https://www.cancer.gov/types/skin) Reason 2 O O
who Reason 2 O O
were Reason 2 O O
recently Reason 2 O O
treated Reason 2 O O
with Reason 2 O O
an Reason 2 O O
immune Reason 2 O O
checkpoint Reason 2 O O
inhibitor. Reason 2 O O
The Reason 2 O O
researchers Reason 2 O O
focused Reason 2 O O
on Reason 2 O O
side Reason 2 O O
effects Reason 2 O O
that Reason 2 O O
were Reason 2 O O
caused Reason 2 O O
by Reason 2 O O
the Reason 2 O O
immune Reason 2 O O
system. Reason 2 O O
More Reason 2 O O
than Reason 2 O O
40% Reason 2 O O
of Reason 2 O O
the Reason 2 O O
patients Reason 2 O O
[developed Reason 2 O O
a Reason 2 O O
long-term Reason 2 O O
immune-related Reason 2 O O
side Reason 2 O O
effect](https://pubmed.ncbi.nlm.nih.gov/33764387/), Reason 2 O O
the Reason 2 O O
researchers Reason 2 O O
reported Reason 2 O O
March Reason 2 O O
25 Reason 2 O O
in Reason 2 O O
JAMA Reason 2 O O
Oncology. Reason 2 O O
Most Reason 2 O O
of Reason 2 O O
these Reason 2 O O
side Reason 2 O O
effects Reason 2 O O
did Reason 2 O O
not Reason 2 O O
go Reason 2 O O
away Reason 2 O O
during Reason 2 O O
the Reason 2 O O
nearly Reason 2 O O
1.5 Reason 2 O O
years Reason 2 O O
that Reason 2 O O
patients Reason 2 O O
were Reason 2 O O
tracked. Reason 2 O O
"These O O O O
therapies O O O O
are O O O O
providing O O O O
the O O O O
opportunity O O O O
for O O O O
long-term O O O O
survival O O O O
for O O O O
many O O O O
patients," O O O O
said O O O O
the O O O O
study's O O O O
leader, O O O O
Douglas O O O O
Johnson, O O O O
M.D., O O O O
of O O O O
Vanderbilt O O O O
University O O O O
Medical O O O O
Center. O O O O
But O O O O
with O O O O
longer O O O O
survival O O O O
comes O O O O
the O O O O
possibility O O O O
of O O O O
long-term O O O O
side O O O O
effects, O O O O
he O O O O
explained. O O O O
Better O O O O
understanding O O O O
the O O O O
long-term O O O O
effects O O O O
of O O O O
immune O O O O
checkpoint O O O O
inhibitors O O O O
is O O O O
increasingly O O O O
important O O O O
because O O O O
these O O O O
drugs O O O O
are O O O O
being O O O O
used O O O O
to O O O O
treat O O O O
more O O O O
kinds O O O O
of O O O O
cancer O O O O
and O O O O
in O O O O
more O O O O
treatment O O O O
combinations, O O O O
Dr. O O O O
Johnson O O O O
added. O O O O
The O O O O
bottom O O O O
line O O O O
is O O O O
that O O O O
doctors O O O O
should O O O O
talk O O O O
with O O O O
their O O O O
patients O O O O
about O O O O
the O O O O
possibility O O O O
of O O O O
chronic O O O O
side O O O O
effects, O O O O
he O O O O
said, O O O O
so O O O O
they O O O O
can O O O O
weigh O O O O
the O O O O
potential O O O O
benefits O O O O
and O O O O
harms O O O O
